Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study
- Resource Type
- Article
- Source
- In
The Lancet Rheumatology September 2023 5(9):e532-e541 - Subject
Primary Research Articles - Language
- ISSN
- 2665-9913